OR WAIT null SECS
June 01, 2023
Through the acquisition, Avacta gains Coris’ product portfolio consisting of diagnostic tests for respiratory, gastroenteric, and blood-borne pathogens as well as for the detection of antibiotic resistance markers.
May 31, 2023
Under the new MTA and Option License Agreement, Adcendo can nominate ADCs against two novel ADC targets, according to the press release.
May 30, 2023
The $87.5 million purchase grants Novartis rights to an investigational gene therapy program intended for treatment of cystinosis.
May 23, 2023
uBriGene Biosciences will acquire Mustang Bio’s Worcester, Mass., CGT manufacturing facility in a deal worth up to $11 million, expanding its operations into the US market.
May 18, 2023
Waters Corporation expected to boost growth in bioanalytical characterization for new modalities with acquisition of Wyatt Technology.
May 17, 2023
This deal would help the companies merge to work on future projects and conduct research together.
May 15, 2023
Forge will provide adeno-associated virus (AAV) process development, toxicology, cGMP manufacturing, and analytical services to Life Bio, which will occur at Forge’s gene therapy facility in Columbus, Ohio called the Hearth.
May 12, 2023
This approach is defined as being used to express transcription factor combinations to reprogram human induced pluripotent stem cells (iPSCs).
May 11, 2023
The objective of the partnership is to automate portions of ScaleReady’s CGT manufacturing workflow by using Cellular Origin’s robotic system for sterile liquid transfer.
Critical raw materials supplier, Biosynth, has acquired UK-based Cambridge Research Biochemicals (CRB).